7 US Peptide Rules Every Researcher Should Know in 2026

Seven rules that decide what is and is not allowed with peptides in the United States in 2026, from FDA approval and research-use-only labels to the October HHS compounding policy. Each rule links to the official record. This is a summary for researchers, not legal advice. Checked 22 November 2026.
The 7 rules at a glance
- Research peptides are not FDA-approved drugs
- A “research use only” label is not a shield
- Only licensed 503A pharmacies are covered by the HHS policy
- The July 2026 FDA vote was advice, not approval
- GLP-1 research products draw the most enforcement
- Check every seller against the FDA warning letter list
- Weak enforcement does not mean quality is checked
1. Research peptides are not FDA-approved drugs
None of the popular research peptides, from BPC-157 to retatrutide, is an FDA-approved medicine. Selling them for use in people is selling an unapproved drug. Details: are peptides legal?
2. A “research use only” label is not a shield
FDA judges what a product is for from the whole website. Its 2026 warning letters cited dosing guides, peptide calculators sold next to bacteriostatic water, health claims and GLP-1 code names such as “GLP-3 Reta”. The five letters of 24 August 2026 rejected research-use labels as cover.
3. Only licensed 503A pharmacies are covered by the HHS policy
On 30 October 2026 HHS published an interim enforcement discretion policy (91 FR 68526) for six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. It covers state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A, with an FDA-registered source, a full COA and one peptide per product. It does not cover research-use-only sales. Explained: the HHS peptide policy.
4. The July 2026 FDA vote was advice, not approval
FDA’s Pharmacy Compounding Advisory Committee recommended the same six peptides for the 503A bulks list on 23 to 24 July 2026 and voted against DSIP. FDA staff had recommended against all seven. Formal rulemaking must follow, which commentators estimate at 6 to 18 months. More: FDA peptide vote.
5. GLP-1 research products draw the most enforcement
Semaglutide, tirzepatide and retatrutide appear in most FDA letters to research-peptide sellers, and Eli Lilly filed civil suits against research-retatrutide sellers in August 2026. None of the six-peptide relief applies to them.
6. Check every seller against the FDA warning letter list
Our tracker lists 17 letters from February 2024 to August 2026, from SwissChems to Peptide Partners. A supplier with a letter on file is never listed on this site. Tracker: FDA peptide warning letters.
7. Weak enforcement does not mean quality is checked
Public Citizen’s 19 November 2026 report argues FDA enforcement on unapproved peptides largely stopped in 2025. If nobody checks the market, the lab has to: lot-matched COAs, mass-spec identity and measured content. Report summary: Public Citizen on FDA peptide enforcement. Checklist: verify a peptide COA.
Timeline: US peptide rules, 2024 to 2026
| Date | Event |
|---|---|
| Feb 2024 | First FDA letters to research-peptide sellers (US Chem Labs, Helix Chemical Supply) |
| Dec 2024 | Letters to Prime Peptides, Summit Research Peptides and SwissChems |
| 31 Mar 2026 | Five more letters, including Prime Sciences and Gram Peptides |
| 15 Apr 2026 | BPC-157 and Epitalon removed from FDA’s Category 2 bulks list after nominations were withdrawn |
| 23–24 Jul 2026 | FDA advisory committee recommends six peptides for the 503A bulks list |
| 24 Aug 2026 | Five warning letters reject “research use only” labels |
| 30 Oct 2026 | HHS interim 503A policy published (91 FR 68526) |
| 13 Nov 2026 | Comment period on the HHS policy closes |
| 19 Nov 2026 | Public Citizen report on FDA enforcement |
Choosing a lab supplier: top 10 peptide vendors in the USA · how we verify suppliers.
Frequently asked questions
Buying a research chemical for laboratory research is not the issue regulators target. Selling or using unapproved peptides for people is: none of the popular research peptides is FDA-approved, and FDA has said a research-use-only label does not protect a seller whose site shows human use.
HHS said it will not take enforcement action against licensed 503A pharmacies that compound BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c under strict conditions (Federal Register, 30 October 2026, 91 FR 68526). It is interim, it is not FDA approval and it does not cover research-use-only products.
No. In July 2026 an FDA advisory committee narrowly recommended BPC-157 and five other peptides for the 503A bulks list. That vote is advice only; FDA rulemaking must follow.
Our tracker lists 17 letters to research-peptide sellers from February 2024 to August 2026, including five on 24 August 2026. GLP-1 compounds appear in most of them.
Every peptide outside the six, including GHK-Cu, Selank, DSIP, retatrutide and tirzepatide research products, and all blends.
Sources
- Federal Register: HHS enforcement discretion policy, 503A compounding with certain peptides (30 Oct 2026, 91 FR 68526)
- FDA warning letter: Peptide Partners LLC (24 Aug 2026)
- FDA warning letter: Prime Sciences (31 Mar 2026)
- Public Citizen: Asleep at the Vial (19 Nov 2026)
- Holland & Knight: HHS interim enforcement discretion policy (Nov 2026)
- RAPS: HHS will permit compounding of six peptides (29 Oct 2026)
Checked 22 November 2026. Peptides in Lab is an independent education site. For laboratory research use only; not for human or veterinary use.
An independent reference for researchers in the US, UK and EU: compound profiles, lab tools and supplier checks.
For research and educational purposes only. Compounds described here are sold by third parties for laboratory research and are not approved for human or veterinary use. We do not provide dosing or treatment information. Some links earn us a commission at no cost to you. © 2026 Peptides in Lab.
Deal of the week50% off research peptides
Code IZBA50OFF at Ascension Peptides (US).
- Lumin:
IZBA1010% off (US) - Bench Grade:
IZBA+10% first order (US) - PX1 Research:
59A4F18915% off (US) - Simms:
IZBA07210% first order (US) - CertaPeptides:
AFF-IZBATAZEEM10% off (EU/UK)
Get 50% off now →See all codes and pricesAd · affiliate link · Research use only
